ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Ixabepilone in Treating Patients With Renal Cell Carcinoma (Kidney Cancer)

This study is currently recruiting participants.
Verified by National Cancer Institute (NCI), November 2008

Sponsors and Collaborators: NCI - Center for Cancer Research-Medical Oncology
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00033670
  Purpose

RATIONALE: Drugs used in chemotherapy, such as ixabepilone (BMS-247550), work in different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well ixabepilone works in treating patients with renal cell carcinoma (kidney cancer).


Condition Intervention Phase
Kidney Cancer
Drug: ixabepilone
Phase II

MedlinePlus related topics:   Cancer    Kidney Cancer   

Drug Information available for:   Epothilone B    Ixabepilone   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Open Label
Official Title:   A Phase II Clinical Trial Of BMS-247550 (NSC 710428), an Epothilone B Analog, in Renal Cell Carcinoma

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Activity [ Designated as safety issue: No ]
  • Plasma pharmacokinetics and pharmacodynamics [ Designated as safety issue: No ]
  • Nerve growth factor (NGF) levels [ Designated as safety issue: No ]
  • Correlation of NGF levels with neurotoxicity [ Designated as safety issue: Yes ]
  • Differences between responding and non-responding tumors as assessed by cDNA microarray [ Designated as safety issue: No ]

Estimated Enrollment:   114
Study Start Date:   February 2002
Estimated Primary Completion Date:   December 2009 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES:

Primary

  • Determine the activity of ixabepilone in patients with renal cell carcinoma.
  • Determine the plasma pharmacokinetics and pharmacodynamics of this drug using an assay that measures the relative amounts of polymerized versus unpolymerized endogenous tubulin in peripheral blood mononuclear cells of these patients.
  • Determine the nerve growth factor (NGF) levels in patients before and after receiving this drug.
  • Determine the correlation (if any) between NGF levels in these patients and neurotoxicity of this drug.
  • If this drug is found to be active in more than 20% of these patients, determine whether differences exist between responding and non-responding tumors by analyzing tumor samples using cDNA microarray.

Secondary

  • Determine the extent to which pharmacodynamic changes are observed over a range of doses of ixabepilone.
  • Determine if cross-resistance to ixabepilone exists in patients who have received prior sorafenib or sunitinib.

OUTLINE: Patients are stratified according to histologic subtype (clear cell vs type I or II papillary vs chromophobe, collecting duct, or medullary).

Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 36-114 patients (12-74 per stratum) will be accrued for this study within 7-48 months.

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed renal cell carcinoma

    • Eligible subtypes:

      • Clear cell
      • Type I or II papillary
      • Chromophobe
      • Collecting duct
      • Medullary
  • Received prior, ineligible for, or refused interleukin-2
  • Measurable disease
  • No prior CNS metastases unless control was achieved with radiotherapy or surgical resection at least 6 months before study entry
  • Must meet 1 of the following criteria:

    • Received sorafenib and/or sunitinib and had progressive disease while receiving the drugs
    • Evaluated for therapy with sorafenib and/or sunitinib and deemed to be ineligible
    • Evaluated for therapy with sorafenib and/or sunitinib and refused treatment

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • At least 3 months

Hematopoietic:

  • Platelet count at least 100,000/mm^3
  • Absolute granulocyte count at least 1,500/mm^3

Hepatic:

  • Bilirubin no greater than 1.5 times normal (3 times normal if clinical evidence of Gilbert's disease)
  • SGPT and SGOT no greater than 2.5 times normal

Renal:

  • Creatinine no greater than 1.6 mg/dL OR
  • Creatinine clearance at least 40 mL/min

Other:

  • HIV negative
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 2 months after study completion
  • No other serious concurrent medical illness
  • No active, uncontrolled infection
  • No other nonmalignant systemic disease that would preclude study participation
  • No grade 2 or greater motor or sensory neuropathy
  • No prior hypersensitivity reactions to agents containing Cremophor EL

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • See Disease Characteristics
  • At least 4 weeks since prior immunotherapy
  • Prior thalidomide allowed

Chemotherapy:

  • At least 4 weeks since prior cytotoxic chemotherapy
  • No other prior chemotherapy

Endocrine therapy:

  • Not specified

Radiotherapy:

  • See Disease Characteristics
  • No prior craniospinal or total body irradiation
  • At least 4 weeks since other prior radiotherapy

Surgery:

  • See Disease Characteristics

Other:

  • No other concurrent investigational drugs
  • No concurrent Hypericum perforatum (St. John's Wort)
  • At least 2 weeks since prior targeted-therapy (cytostatic agents) and recovered
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00033670

Locations
United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office     Recruiting
      Bethesda, Maryland, United States, 20892-1182
      Contact: Clinical Trials Office - Warren Grant Magnusen Clinical Center     888-NCI-1937        

Sponsors and Collaborators
NCI - Center for Cancer Research-Medical Oncology
National Cancer Institute (NCI)

Investigators
Principal Investigator:     Antonio T. Fojo, MD, PhD     NCI - Center for Cancer Research-Medical Oncology    
  More Information


Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site
 
Web site for additional information  This link exits the ClinicalTrials.gov site
 

Responsible Party:   NCI - Cancer Therapeutics Branch ( Antonio Tito Fojo )
Study ID Numbers:   CDR0000069310, NCI-02-C-0130, NCI-3654
First Received:   April 9, 2002
Last Updated:   November 25, 2008
ClinicalTrials.gov Identifier:   NCT00033670
Health Authority:   Unspecified

Keywords provided by National Cancer Institute (NCI):
stage I renal cell cancer  
stage II renal cell cancer  
stage III renal cell cancer  
stage IV renal cell cancer
recurrent renal cell cancer
clear cell renal cell carcinoma

Study placed in the following topic categories:
Epothilone B
Epothilones
Urogenital Neoplasms
Renal cancer
Urologic Neoplasms
Kidney cancer
Recurrence
Carcinoma
Urologic Diseases
Kidney Neoplasms
Carcinoma, Renal Cell
Kidney Diseases
Adenocarcinoma
Clear cell renal cell carcinoma
Urinary tract neoplasm
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site
Neoplasms by Histologic Type
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Therapeutic Uses
Mitosis Modulators
Tubulin Modulators
Antimitotic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 30, 2008




Links to all studies - primarily for crawlers